Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.

Scheiner B, Stättermayer AF, Schwabl P, Bucsics T, Paternostro R, Bauer D, Simbrunner B, Schmidt R, Marculescu R, Ferlitsch A, Peck-Radosavljevic M, Pinter M, Trauner M, Reiberger T, Ferenci P, Mandorfer M.

Liver Int. 2020 Feb;40(2):393-404. doi: 10.1111/liv.14304. Epub 2019 Dec 3.

2.

Corrigendum to 'Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study' [J Hepatol 67 (2017) 940-949].

Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rosi S, MacDonald S, Malago M, Stepanova M, Younossi ZM, Trepte C, Watson R, Borisenko O, Sun S, Inhaber N, Jalan R.

J Hepatol. 2020 Mar;72(3):595-596. doi: 10.1016/j.jhep.2019.11.023. Epub 2020 Jan 9. No abstract available.

PMID:
31928862
3.

Securing sustainable funding for viral hepatitis elimination plans.

Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP.

Liver Int. 2020 Feb;40(2):260-270. doi: 10.1111/liv.14282. Epub 2019 Dec 5. Review.

PMID:
31808281
4.

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.

Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ.

Hepatology. 2019 Nov 7. doi: 10.1002/hep.31022. [Epub ahead of print]

PMID:
31698504
5.

Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient.

Mandorfer M, Peck-Radosavljevic M, Ferenci P, Reiberger T.

Liver Int. 2019 Oct 15. doi: 10.1111/liv.14273. [Epub ahead of print] No abstract available.

PMID:
31612610
6.

A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia.

Newland A, Bentley R, Jakubowska A, Liebman H, Lorens J, Peck-Radosavljevic M, Taieb V, Takami A, Tateishi R, Younossi ZM.

Hematology. 2019 Dec;24(1):679-719. doi: 10.1080/16078454.2019.1662200.

PMID:
31581933
7.

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.

Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P.

J Hepatol. 2019 Dec;71(6):1164-1174. doi: 10.1016/j.jhep.2019.08.006. Epub 2019 Aug 14.

PMID:
31421157
8.

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.

Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T.

Hepatology. 2020 Mar;71(3):1023-1036. doi: 10.1002/hep.30885. Epub 2019 Oct 14.

9.

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M.

United European Gastroenterol J. 2019 Jul;7(6):850-858. doi: 10.1177/2050640619840199. Epub 2019 Mar 21.

10.

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M.

Liver Cancer. 2019 May;8(3):203-217. doi: 10.1159/000489833. Epub 2018 Jun 22.

11.

Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.

Turco L, Villanueva C, La Mura V, García-Pagán JC, Reiberger T, Genescà J, Groszmann RJ, Sharma BC, Merkel C, Bureau C, Alvarado E, Abraldes JG, Albillos A, Bañares R, Peck-Radosavljevic M, Augustin S, Sarin SK, Bosch J, García-Tsao G.

Clin Gastroenterol Hepatol. 2020 Feb;18(2):313-327.e6. doi: 10.1016/j.cgh.2019.05.050. Epub 2019 Jun 5.

PMID:
31176013
12.

High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.

Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, Aichelburg MC, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T.

United European Gastroenterol J. 2019 May;7(4):507-516. doi: 10.1177/2050640619835394. Epub 2019 Mar 6.

13.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M.

Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.

14.

Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.

Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, Paternostro R, Scheiner B, Wöran K, Pinter M, Stättermayer AF, Trauner M, Peck-Radosavljevic M, Ferlitsch A, Reiberger T.

Dig Liver Dis. 2019 Aug;51(8):1144-1151. doi: 10.1016/j.dld.2019.01.020. Epub 2019 Feb 12.

PMID:
30862438
15.

DAAs prevent HCC - the plot thickens.

Peck-Radosavljevic M, Singal AK.

Dig Liver Dis. 2019 Apr;51(4):460-461. doi: 10.1016/j.dld.2019.01.027. Epub 2019 Feb 11. No abstract available.

PMID:
30827865
16.

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).

Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N.

Hepatology. 2019 Oct;70(4):1336-1348. doi: 10.1002/hep.30561. Epub 2019 Mar 15.

17.

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis.

Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Bardach C, Lampichler K, Seeland B, Schwarzer R, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Hepatol Res. 2019 Feb;49(2):201-211. doi: 10.1111/hepr.13253. Epub 2018 Oct 31.

PMID:
30248213
18.

Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.

Bucsics T, Grasl B, Ferlitsch A, Schwabl P, Mandorfer M, Zinober K, Stern R, Chromy D, Scheiner B, Sieghart W, Peck-Radosavljevic M, Trauner M, Reiberger T.

Ultrasound Med Biol. 2018 Dec;44(12):2578-2586. doi: 10.1016/j.ultrasmedbio.2018.07.031. Epub 2018 Sep 18.

PMID:
30241728
19.

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 161: A 42-year-old journalist with fatigue, elevated liver function tests, hyperglycemia and pruritus.

Fabian E, Peck-Radosavljevic M, Krones E, Mueller H, Lackner C, Spreizer C, Putz-Bankuti C, Fuerst W, Wutte N, Fickert P, Mischinger H, Krejs GJ.

Wien Klin Wochenschr. 2018 Sep;130(17-18):545-556. doi: 10.1007/s00508-018-1379-z. Epub 2018 Aug 21. No abstract available.

20.

Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI.

Haider L, Mandorfer M, Güngören Z, Reiberger T, Bastati N, Hodge JC, Chromy D, Trauner M, Herold C, Peck-Radosavljevic M, Ba-Ssalamah A.

Contrast Media Mol Imaging. 2018 Jul 12;2018:8489709. doi: 10.1155/2018/8489709. eCollection 2018.

21.

Liver disease in adults with α1-antitrypsin deficiency.

Mandorfer M, Bucsics T, Hutya V, Schmid-Scherzer K, Schaefer B, Zoller H, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Ferenci P, Kneussl M, Reiberger T.

United European Gastroenterol J. 2018 Jun;6(5):710-718. doi: 10.1177/2050640618764057. Epub 2018 Feb 28.

22.

Review article: systemic treatment of hepatocellular carcinoma.

Pinter M, Peck-Radosavljevic M.

Aliment Pharmacol Ther. 2018 Sep;48(6):598-609. doi: 10.1111/apt.14913. Epub 2018 Jul 23. Review.

23.

Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.

Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M, Coulouarn C, Schreiner W, Schlangen K, Sieghart W, Peck-Radosavljevic M, Mikulits W.

Hepatology. 2019 Jan;69(1):222-236. doi: 10.1002/hep.30166. Epub 2018 Dec 20.

24.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
25.

Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension.

Mandorfer M, Scheiner B, Stättermayer AF, Schwabl P, Paternostro R, Bauer D, Schaefer B, Zoller H, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferenci P, Ferlitsch A.

Aliment Pharmacol Ther. 2018 Aug;48(4):451-459. doi: 10.1111/apt.14856. Epub 2018 Jun 29.

26.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. doi: 10.1158/1078-0432.CCR-17-3588. Epub 2018 Jun 27.

27.

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.

Schwabl P, Brusilovskaya K, Supper P, Bauer D, Königshofer P, Riedl F, Hayden H, Fuchs CD, Stift J, Oberhuber G, Aschauer S, Bonderman D, Gnad T, Pfeifer A, Uschner FE, Trebicka J, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Trauner M, Reiberger T.

Sci Rep. 2018 Jun 19;8(1):9372. doi: 10.1038/s41598-018-27656-y.

28.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
29.

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.

Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T.

Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22.

30.

Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.

Mandorfer M, Reiberger T, Peck-Radosavljevic M.

Gastroenterology. 2018 Apr;154(5):1550-1551. doi: 10.1053/j.gastro.2017.08.078. Epub 2018 Mar 8. No abstract available.

PMID:
29526728
31.

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.

Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, Hayden H, Reiberger T, Schulte-Hermann R, Peck-Radosavljevic M, Stoiber D, Trauner M.

Oncotarget. 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300. eCollection 2018 Feb 9.

32.

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.

Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP.

J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. doi: 10.1111/jvh.12875. Review.

PMID:
29508946
33.

Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.

Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Aliment Pharmacol Ther. 2018 Apr;47(8):1162-1169. doi: 10.1111/apt.14576. Epub 2018 Feb 28.

34.

Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study.

Stepanova M, Nader F, Bureau C, Adebayo D, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rossi S, MacDonald S, Capel J, Jalan R, Younossi ZM.

Qual Life Res. 2018 Jun;27(6):1513-1520. doi: 10.1007/s11136-018-1813-8. Epub 2018 Feb 19.

PMID:
29460201
35.

Young gastrointestinal angle: How to prepare and submit a job application.

Nakov R, Peck-Radosavljevic M.

United European Gastroenterol J. 2018 Feb;6(1):160-161. doi: 10.1177/2050640618754756. Epub 2018 Jan 22. No abstract available.

36.

Corrigendum to "Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [J Hepatol 67 (2017) 940-949].

Bureau C, Adebayo D, de Rieu MC, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Abbadi R, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rosi S, MacDonald S, Malago M, Stepanova M, Younossi ZM, Trepte C, Watson R, Borisenko O, Sun S, Inhaber N, Jalan R.

J Hepatol. 2018 Mar;68(3):630. doi: 10.1016/j.jhep.2017.12.017. Epub 2018 Feb 1. No abstract available.

PMID:
29395458
37.

Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.

Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T.

Aliment Pharmacol Ther. 2018 Apr;47(7):966-979. doi: 10.1111/apt.14485. Epub 2018 Feb 1.

38.

Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.

Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A; Vienna Hepatic Hemodynamic Lab.

Aliment Pharmacol Ther. 2018 Apr;47(7):980-988. doi: 10.1111/apt.14522. Epub 2018 Jan 29.

39.

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.

Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Schwarzer R, Seeland B, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Liver Int. 2018 Aug;38(8):1427-1436. doi: 10.1111/liv.13704. Epub 2018 Feb 20.

40.

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, Mandorfer M, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

PLoS One. 2018 Jan 9;13(1):e0189414. doi: 10.1371/journal.pone.0189414. eCollection 2018.

41.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.

United European Gastroenterol J. 2017 Nov;5(7):987-996. doi: 10.1177/2050640617695698. Epub 2017 Feb 26.

42.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

43.

Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension.

Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Aliment Pharmacol Ther. 2018 Jan;47(1):86-94. doi: 10.1111/apt.14377. Epub 2017 Nov 3.

44.

ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.

Bucsics T, Hoffman S, Grünberger J, Schoder M, Matzek W, Stadlmann A, Mandorfer M, Schwabl P, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Karner J, Karnel F, Reiberger T.

Liver Int. 2018 Jun;38(6):1036-1044. doi: 10.1111/liv.13615. Epub 2018 Jan 15.

PMID:
29091351
45.

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P.

Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158. doi: 10.1007/s00508-017-1262-3. Epub 2017 Oct 23.

46.

Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.

Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M.

Oncotarget. 2017 Jul 6;8(34):57109-57120. doi: 10.18632/oncotarget.19055. eCollection 2017 Aug 22.

47.

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

Dig Liver Dis. 2017 Dec;49(12):1360-1367. doi: 10.1016/j.dld.2017.08.002. Epub 2017 Aug 8.

PMID:
28869158
48.

The impact of thyroid hormones on patients with hepatocellular carcinoma.

Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, Sieghart W.

PLoS One. 2017 Aug 3;12(8):e0181878. doi: 10.1371/journal.pone.0181878. eCollection 2017.

49.

Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging.

Wengert GJ, Baltzer PAT, Bickel H, Thurner P, Breitenseher J, Lazar M, Pones M, Peck-Radosavljevic M, Hucke F, Ba-Ssalamah A.

Acad Radiol. 2017 Dec;24(12):1491-1500. doi: 10.1016/j.acra.2017.06.005. Epub 2017 Jul 26.

PMID:
28756085
50.

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.

Chromy D, Schwabl P, Bucsics T, Scheiner B, Strassl R, Mayer F, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M.

Wien Klin Wochenschr. 2018 Feb;130(3-4):105-114. doi: 10.1007/s00508-017-1231-x. Epub 2017 Jul 25.

Supplemental Content

Loading ...
Support Center